X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs PANACEA BIOTECH - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD PANACEA BIOTECH WYETH LTD/
PANACEA BIOTECH
 
P/E (TTM) x 27.7 171.2 16.2% View Chart
P/BV x 5.3 3.8 140.6% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    WYETH LTD
Mar-13
PANACEA BIOTECH
Mar-14
WYETH LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,044149 702.4%   
Low Rs81882 993.9%   
Sales per share (Unadj.) Rs298.684.1 354.8%  
Earnings per share (Unadj.) Rs57.2-18.3 -312.7%  
Cash flow per share (Unadj.) Rs58.4-6.7 -872.0%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.583.7 298.0%  
Shares outstanding (eoy) m22.7261.25 37.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.4 227.2%   
Avg P/E ratio x16.3-6.3 -257.9%  
P/CF ratio (eoy) x15.9-17.2 -92.5%  
Price / Book Value ratio x3.71.4 270.5%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1577,074 299.1%   
No. of employees `0000.52.8 17.9%   
Total wages/salary Rs m4001,449 27.6%   
Avg. sales/employee Rs Th13,787.41,874.1 735.7%   
Avg. wages/employee Rs Th813.0527.0 154.3%   
Avg. net profit/employee Rs Th2,643.3-407.7 -648.3%   
INCOME DATA
Net Sales Rs m6,7835,154 131.6%  
Other income Rs m353100 353.3%   
Total revenues Rs m7,1365,254 135.8%   
Gross profit Rs m1,617-766 -211.1%  
Depreciation Rs m27711 3.7%   
Interest Rs m61,503 0.4%   
Profit before tax Rs m1,938-2,881 -67.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-51,771 -0.3%   
Tax Rs m63217 3,763.1%   
Profit after tax Rs m1,301-1,121 -116.0%  
Gross profit margin %23.8-14.9 -160.3%  
Effective tax rate %32.6-0.6 -5,593.8%   
Net profit margin %19.2-21.8 -88.1%  
BALANCE SHEET DATA
Current assets Rs m6,9843,810 183.3%   
Current liabilities Rs m2,0568,365 24.6%   
Net working cap to sales %72.6-88.4 -82.2%  
Current ratio x3.40.5 745.8%  
Inventory Days Days99156 63.8%  
Debtors Days Days2467 35.6%  
Net fixed assets Rs m24414,480 1.7%   
Share capital Rs m22761 370.6%   
"Free" reserves Rs m5,441903 602.5%   
Net worth Rs m5,6685,127 110.5%   
Long term debt Rs m255,832 0.4%   
Total assets Rs m7,90119,433 40.7%  
Interest coverage x353.3-0.9 -38,551.8%   
Debt to equity ratio x01.1 0.4%  
Sales to assets ratio x0.90.3 323.7%   
Return on assets %16.52.0 841.6%  
Return on equity %22.9-21.9 -104.9%  
Return on capital %34.03.6 936.3%  
Exports to sales %0.224.5 0.9%   
Imports to sales %36.310.2 356.9%   
Exports (fob) Rs m151,264 1.2%   
Imports (cif) Rs m2,465525 469.8%   
Fx inflow Rs m151,539 1.0%   
Fx outflow Rs m2,677942 284.2%   
Net fx Rs m-2,662597 -445.7%   
CASH FLOW
From Operations Rs m923599 154.1%  
From Investments Rs m317-438 -72.4%  
From Financial Activity Rs m-481-303 159.0%  
Net Cashflow Rs m759-141 -537.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.6 1,883.3%  
FIIs % 7.2 1.3 553.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 23.6 128.8%  
Shareholders   21,978 10,259 214.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - GLENMARK PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS